PAR, a novel marker gene for breast and prostate cancers

• US 7,510,707 B2
• Filed: 06/24/2002
• Issued: 03/31/2009
• Est. Priority Date: 12/20/1999
• Status: Expired due to Term

• Current Assignee: Mt. Sinai School Of Medicine
• Original Assignee: Mount Sinai School of Medicine of New York University
• Inventors: Platica, Micsunica, Platica, Ovidu, Holland, James F.
• Primary Examiner(s): Yu; Misook
• Application Number:
  US10/178,389
• Publication Number:
  US 20030005471A1
• Time in Patent Office: 2,472 Days
• Field of Search: 530/350, 530/387.1, 424/130.1, 514/2
• US Class Current: 424/130.1
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: C07K 14/4748 Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE

Abstract

The present invention relates to a gene selectively expressed in malignant cells and associated with the development of androgen resistance in prostate cancer. Levels of the gene, termed “PAR” (for Prostate Androgen Regulated), its RNA transcript, and its protein product are all present at increased levels in malignant cells, such as breast cancer and prostate cancer cells. The present invention provides for PAR nucleic acid molecules and proteins, for antibodies that specifically bind to PAR proteins, and to methods for diagnosing and treating cancers that utilize such molecules.

Claims

1. A method of inhibiting the proliferation of a cell, comprising inhibiting prostate androgen regulated (PAR) protein in said cell,

wherein said inhibiting comprises contacting said PAR protein of said cell with an antibody preparation, wherein said antibody preparation comprises an antibody immunologically reactive with a PAR protein comprising of SEQ ID NO:

2; and

wherein said antibody preparation binds to and inhibits said PAR protein.

2. The method of claim 1, wherein said cell is a malignant cell.

3. The method of claim 1, wherein said cell is a cancer cell selected from the group consisting of a prostate cell, a breast cell, a brain cell, gallbladder cell, an ovarian cell, a lung cell, a stomach cell, a kidney cell, a uterus cell, a duodenum cell, a ureter cell, a thyroid cell, a colon cell, a bladder cell, an adrenal cell, a rectum cell, a thymus cell, a liver cell, and a lymphoma cell.

4. The method of claim 1, wherein said cell is a non-malignant proliferative cell.

5. The method of claim 4, wherein said cell is a vascular endothelial cell.

6. The method of claim 1, wherein said antibody preparation comprises a polyclonal antibody preparation.

7. The method of claim 1, wherein said antibody preparation consists essentially of a monoclonal antibody preparation.

8. The method of claim 1, wherein said antibody preparation comprises a single chain antibody preparation.

9. The method of claim 1, wherein said antibody comprises a chimeric antibody.

10. The method of claim 3, wherein said cell is a breast cancer cell.

11. The method of claim 3, wherein said cell is a prostate cancer cell.

22. The method according to claim 1 wherein said antibody preparation inactivates said PAR protein.

12. A method of inhibiting the malignant transformation of a cell comprising inhibiting PAR protein of said cell,

wherein said inhibiting comprises contacting said PAR protein of said cell with an antibody preparation, wherein said antibody preparation comprises an antibody immunologically reactive with a PAR protein comprising of SEQ ID NO:

2; and

wherein said antibody preparation binds to and inhibits said PAR protein.

13. The method of claim 12, wherein said cell is a breast cancer cell.

14. The method of claim 12, wherein said breast cancer cell is a primary breast cancer cell.

15. The method of claim 12, wherein said cell is a prostate cancer cell.

23. The method according to claim 12 wherein said antibody preparation inactivates said PAR protein.

16. A method of treating breast cancer in a subject, comprising identifying the subject having an increased expression of PAR protein in the breast cancer cells:

a) contacting cells of said subject with an anti-PAR antibody preparation,

polypeptide

variant

wherein said antibody preparation comprises an antibody immunologically reactive with a PAR protein comprising of SEQ ID NO;

2; and

wherein said antibody preparation binds to and inhibits said PAR protein.

17. The method of claim 16, wherein said antibody preparation comprises a polyclonal antibody preparation.

18. The method of claim 16, wherein said antibody preparation comprises a monoclonal antibody preparation.

24. The method according to claim 16 wherein said antibody preparation inactivates said PAR protein.

19. A method of treating prostate cancer in a subject, comprising:

diagnosing

a) contacting the cells of said subject with an anti-PAR antibody preparation,

wherein said antibody preparation comprises an antibody immunologically reactive with a PAR protein comprising of SEQ ID NO;

2; and

wherein said antibody preparation binds to and inhibits said PAR protein.

20. The method of claim 19, wherein said antibody preparation comprises a polyclonal antibody preparation.

21. The method of claim 19, wherein said antibody preparation comprises a monoclonal antibody preparation.

25. The method according to claim 19 wherein said antibody preparation inactivates said PAR protein.